ArticlePLoS pathogens2025
TRIM28 is a target for paramyxovirus V proteins.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.Immunologic research · 2026Review
- Locust cGAS-like Receptors Recognize Derivatives of a Gypsy Retrotransposon to Synergize with RNAi Against Viral Invasion.Insects · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
SUMO-modified Tripartite Motif Protein 28 (TRIM28; KAP1) plays a crucial role in repressing endogenous retroelement (ERE) transcription. We previously provided evidence that loss of SUMO-modified TRIM28 triggered by influenza A virus (IAV) infection promotes activation of host antiviral immunity via a mechanism involving derepression of EREs and production of immunostimulatory RNAs. While the IAV NS1 protein might limit consequences of such activation via its dsRNA-binding activity, we hypothesized that other human pathogenic viruses could have evolved more direct strategies to counteract this potential ERE-based defense system. Here, we reveal that V proteins from diverse paramyxoviruses, including Measles, Mumps, Parainfluenza, and Nipah/Hendra viruses, can all engage with TRIM28. Notably, the efficiency of engagement varies markedly between virus species, a phenotype that can be linked to specific residues within the C-terminal domain of V proteins. Further mapping showed that V proteins target both the TRIM28 Coiled-Coil domain and the TRIM28 PHD-Bromodomain, which contains the functionally-relevant TRIM28 SUMO-modification sites necessary for ERE repression. In this context, while paramyxovirus infection triggers canonical stress-associated phosphorylation of TRIM28, loss of SUMO-modified TRIM28 does not occur, and minimal induction of the TRIM28-dependent ERE RNA, HERVK14C, is observed. Furthermore, pre-infection with Parainfluenza virus type 2, which encodes a V protein that efficiently engages with TRIM28, limits subsequent IAV-triggered loss of SUMO-modified TRIM28 and upregulation of HERVK14C RNA. These findings dissect the interplay between paramyxoviruses and TRIM28, providing support for the concept of a TRIM28-regulated ERE-based antiviral defense system by uncovering a potential viral antagonistic measure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.